Patents by Inventor Shunguang Wang

Shunguang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GALECTIN-3 IMMUNOASSAY
    Publication number: 20240103018
    Abstract: The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.
    Type: Application
    Filed: March 24, 2023
    Publication date: March 28, 2024
    Inventors: Pieter Muntendam, Shunguang Wang
  • GALECTIN-3 IMMUNOASSAY
    Publication number: 20200033367
    Abstract: The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.
    Type: Application
    Filed: June 18, 2019
    Publication date: January 30, 2020
    Inventors: Pieter Muntendam, Shunguang Wang
  • GALECTIN-3 IMMUNOASSAY
    Publication number: 20170370944
    Abstract: The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.
    Type: Application
    Filed: February 3, 2017
    Publication date: December 28, 2017
    Inventors: Pieter Muntendam, Shunguang Wang
  • ASSESSING CONGESTIVE HEART RISK IN PATIENTS TREATED OR POTENTIALLY TO BE TREATED WITH A PEROXISOME-PROLIFERATOR-ACTIVATOR-RECEPTOR-GAMMA AGONIST OR A THIAZOLIDINEDIONE
    Publication number: 20110046187
    Abstract: Methods are provided for assessing a patient being treated with a peroxisome-proliferator-activator-receptor-? (PPAR-?) agonist or a thiazolidinedione (TZD), or having a condition treatable with a peroxisome-proliferator-activator-receptor-?agonist or a thiazolidinedione. Methods include measuring a galectin-3 concentration or a change in a galectin-3 concentration in a body fluid of a patient being treated with a peroxisome-proliferator-activator-receptor-? agonist or a thiazolidinedione. A comparison to galectin-3 levels or changes in comparable patients provides information indicative of congestive heart risk.
    Type: Application
    Filed: September 16, 2008
    Publication date: February 24, 2011
    Applicant: BG MEDICINE, INC.
    Inventors: Robert Nicholas McBurney, Shunguang Wang, Tom Plasterer, Pieter Muntendam